LGND Ligand Pharmaceuticals Incorporated

108.47
-0.43  -0%
Previous Close 108.9
Open 108.8
Price To Book 2.42
Market Cap 2,062,174,585
Shares 19,011,474
Volume 331,429
Short Ratio
Av. Daily Volume 408,496
Stock charts supplied by TradingView

NewsSee all news

  1. Ligand Pharmaceuticals Ranked in Deloitte's 2019 Technology Fast 500™

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it ranked in Deloitte's Technology Fast 500™, a listing of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech

  2. Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

    Presentation at the American Society of Nephrology (ASN) Kidney Week 2019 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE)

  3. Ligand to Participate in the Stephens 2019 Nashville Investment Conference

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. The fireside chat is scheduled to

  4. Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

    VICTORIA, Nov. 5, 2019 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that

  5. Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

    VICTORIA, Nov. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

sNDA approval announced June 11, 2018.
KYPROLIS (ASPIRE)
Relapsed Multiple Myeloma
Phase 2a data released March 2, 2018.
RPL554
Cystic fibrosis
FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
FDA approval announced October 1, 2018.
KYPROLIS (ARROW)
Multiple Myeloma
sNDA approved January 17, 2018.
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
Phase 3 trial to be initiated mid-2020.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 negative data released July 23, 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 top-line data due 1H 2021.
Sparsentan - DUPLEX
Focal segmental glomerulosclerosis (FSGS)
Phase 2b trial to be initiated.
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.
VK5211
Acute Hip Fracture
Phase 3 top-line data due 3Q 2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Phase 3 data due no later than early 1Q 2020.
SB206
Molluscum contagiosum skin infection
FDA Approval announced October 24, 2019.
Baxdela
Community-acquired bacterial pneumonia (CABP)
Phase 3 data due 1H 2022.
Sparsentan
IgA nephropathy
Phase 1 data from higher cohorts due in next several months.
APVO436
Acute myeloid leukemia (AML)
Phase 2 data met primary endpoint - August 5, 2019.
RPL554 DPI formulation
Maintenance treatment of COPD
Phase 1 top-line data met primary endpoint - July 10, 2019.
Captisol-enabled (CE) Iohexol program
Contrast-induced Nephropathy
Phase 2b completion of enrolment announced October 17, 2019 with data due around the end of 2019.
Ensifentrine (RPL554) and tiotropium
Chronic obstructive pulmonary disease (COPD)
Phase 2 data from first part of trial due 4Q 2019. Final data 1H 2020.
Ensifentrine (RPL554) - Metered Dose Inhaler
Maintenance treatment of COPD
Phase 3 trial has been initiated by partner CStone Pharmaceuticals.
CS1001
Gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma.

Latest News

  1. Ligand Pharmaceuticals Ranked in Deloitte's 2019 Technology Fast 500™

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it ranked in Deloitte's Technology Fast 500™, a listing of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech

  2. Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

    Presentation at the American Society of Nephrology (ASN) Kidney Week 2019 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE)

  3. Ligand to Participate in the Stephens 2019 Nashville Investment Conference

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. The fireside chat is scheduled to

  4. Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

    VICTORIA, Nov. 5, 2019 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that

  5. Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

    VICTORIA, Nov. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem

  6. Ligand Reports Third Quarter 2019 Financial Results

    Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2019 and provided an operating

  7. Ligand to Report Third Quarter 2019 Results on November 5th

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report third quarter 2019 financial results on November 5, 2019. Ligand's CEO John Higgins, President and COO Matt Foehr and Executive Vice

  8. Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand" or "the Company") announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President

  9. ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

    VICTORIA, Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global

  10. Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

    COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine